Journal of Clinical Oncology, Vol 15, 1844-1852, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial

A Horwich, DT Sleijfer, SD Fossa, SB Kaye, RT Oliver, MH Cullen, GM Mead, R de Wit, PH de Mulder, DP Dearnaley, PA Cook, RJ Sylvester and SP Stenning
Medical Research Council Testicular Tumour Working Party, London, United Kingdom.

PURPOSE: This prospective randomized multicenter trial was designed to evaluate the efficacy of carboplatin plus etoposide and bleomycin (CEB) versus cisplatin plus etoposide and bleomycin (BEP) in first-line chemotherapy of patients with good-risk nonseminomatous germ cell tumors. PATIENTS AND METHODS: Between September 1989 and May 1993, a total of 598 patients with good-risk nonseminomatous germ cell tumors were randomized to receive four cycles of either BEP or CEB. In each cycle, the etoposide dose was 120 mg/m2 on days 1, 2, and 3, and the bleomycin dose was 30 U on day 2. BEP patients received cisplatin at 20 mg/m2/d on days 1 to 5 or 50 mg/m2 on days 1 and 2. For CEB patients, the carboplatin dose was calculated from the glomerular filtration rate to achieve a serum concentration x time of 5 mg/mL x minutes. Chemotherapy was recycled at 21-day intervals to a total of four cycles. RESULTS: Of patients assessable for response, 253 of 268 (94.4%) of those allocated to receive BEP achieved a complete response, compared with 227 of 260 (87.3%) allocated to receive CEB (P = .009). There were 30 treatment failures in the 300 patients allocated to BEP and 79 in the 298 allocated to CEB (log-rank chi 2 = 26.9; P < .001), which led to failure-free rates at 1 year of 91% (95% confidence interval [CI], 88% to 94%) and 77% (95% CI, 72% to 82%), respectively. There were 10 deaths in patients allocated to BEP and 27 in patients allocated to CEB (log-rank chi 2 = 8.77; P = .003), which led to 3-year survival rates of 97% (95% CI, 95% to 99%) and 90% (95% CI, 86% to 94%), respectively. CONCLUSION: With these drug doses and schedules, combination chemotherapy based on carboplatin was inferior to that based on cisplatin. This BEP regimen that contains moderate doses of etoposide and bleomycin is effective in the treatment of patients with good-prognosis metastatic nonseminoma.

This article has been cited by other articles:

				Y. Matsumura Polymeric Micellar Delivery Systems in Oncology Jpn. J. Clin. Oncol., December 1, 2008; 38(12): 793 - 802. [Abstract] [Full Text] [PDF]

				D. M. Green Chemotherapy for the Treatment of Children and Adolescents With Malignant Germ Cell Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3297 - 3298. [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				R. de Wit and K. Fizazi Controversies in the Management of Clinical Stage I Testis Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				N. Marina, W. B. London, A. L. Frazier, S. Lauer, F. Rescorla, B. Cushing, M. H. Malogolowkin, R. P. Castleberry, R. B. Womer, and T. Olson Prognostic Factors in Children With Extragonadal Malignant Germ Cell Tumors: A Pediatric Intergroup Study J. Clin. Oncol., June 1, 2006; 24(16): 2544 - 2548. [Abstract] [Full Text] [PDF]

				P. J. Loehrer Sr and G. J. Bosl Carboplatin for Stage I Seminoma and the Sword of Damocles J. Clin. Oncol., December 1, 2005; 23(34): 8566 - 8569. [Full Text] [PDF]

				M. Brydoy, S. D. Fossa, O. Klepp, R. M. Bremnes, E. A. Wist, T. Wentzel-Larsen, and O. Dahl Paternity Following Treatment for Testicular Cancer J Natl Cancer Inst, November 2, 2005; 97(21): 1580 - 1588. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]

				B. Cushing, R. Giller, J. W. Cullen, N. M. Marina, S. J. Lauer, T. A. Olson, P. C. Rogers, P. Colombani, F. Rescorla, D. F. Billmire, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882 J. Clin. Oncol., July 1, 2004; 22(13): 2691 - 2700. [Abstract] [Full Text] [PDF]

				S. J Kellie, H. Boyce, I. J Dunkel, B. Diez, M. Rosenblum, L. Brualdi, and J. L Finlay Primary Chemotherapy for Intracranial Nongerminomatous Germ Cell Tumors: Results of the Second International CNS Germ Cell Study Group Protocol J. Clin. Oncol., March 1, 2004; 22(5): 846 - 853. [Abstract] [Full Text] [PDF]

				J. Oldenburg, G. C. Alfsen, H. H. Lien, N. Aass, H. Waehre, and S. D. Fossa Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses J. Clin. Oncol., September 1, 2003; 21(17): 3310 - 3317. [Abstract] [Full Text] [PDF]

				J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]

				J. M. O'Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours Ann. Onc., January 1, 2003; 14(1): 91 - 96. [Abstract] [Full Text] [PDF]

				M. L. Harvey, T. R. Geldart, R. Duell, G. M. Mead, and K. Tung Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk? Ann. Onc., February 20, 2002; 13(2): 237 - 242. [Abstract] [Full Text] [PDF]

				K. Fizazi, K.-A. Do, X. Wang, L. Finn, C. J. Logothetis, and R. J. Amato A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial Ann. Onc., January 19, 2002; 13(1): 125 - 134. [Abstract] [Full Text] [PDF]

				D. Dearnaley, R. Huddart, and A Horwich Regular review: Managing testicular cancer BMJ, June 30, 2001; 322(7302): 1583 - 1588. [Full Text] [PDF]

				R. de Wit, J. T. Roberts, P. M. Wilkinson, P. H.M. de Mulder, G. M. Mead, S. D. Fossa, P. Cook, L. de Prijck, S. Stenning, and L. Collette Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J. Clin. Oncol., March 15, 2001; 19(6): 1629 - 1640. [Abstract] [Full Text] [PDF]

				W. H. Meyer, C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial J. Clin. Oncol., January 1, 2001; 19(1): 171 - 182. [Abstract] [Full Text] [PDF]

				J. R. Mann, F. Raafat, K. Robinson, J. Imeson, P. Gornall, M. Sokal, E. Gray, P. McKeever, J. Hale, S. Bailey, et al. The United Kingdom Children's Cancer Study Group's Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity J. Clin. Oncol., November 15, 2000; 18(22): 3809 - 3818. [Abstract] [Full Text] [PDF]

				V.R. Archer, L.J. Billingham, and M.H. Cullen Palliative Chemotherapy: No Longer a Contradiction in Terms Oncologist, December 1, 1999; 4(6): 470 - 477. [Abstract] [Full Text]

				R. S. Go and A. A. Adjei Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin J. Clin. Oncol., January 1, 1999; 17(1): 409 - 409. [Abstract] [Full Text] [PDF]

				D. S. Alberts and R. T. Dorr New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 15 - 34. [Abstract] [Full Text]